Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.

Trends in cancer - 1 Oct 2017

Fernández Ariel

Abstract excerpt

The immune checkpoint blocker pembrolizumab (Keytruda) has proven successful in treating solid tumors harboring a DNA mismatch repair (MMR) deficiency. We show that it is possible to generate a drug-promoted phenotype mimicking the MMR deficiency in solid tumors, and thereby to engineer a generic hypersusceptibility to Keytruda through drug-induced metabolic stress on DNA synthesis. The potential of such...

Topics

Join the communities discussing this publication.

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Biomarkers, Tumor
DNA Mismatch Repair
Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Molecular Targeted Therapy

Programmed Cell Death 1 Receptor

Source

Identifiers

PMID: 28958385
DOI: 10.1016/j.trecan.2017.08.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.PMID 28958385Read ↗

Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer.Semantic proximity Read ↗

Immune Checkpoint Blockade Delays Cancer and Extends Survival in Murine DNA Polymerase Mutator SyndromesSemantic proximity Read ↗

Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cellsSemantic proximity Read ↗

Harnessing the Co-vulnerabilities of Amino Acid-Restricted CancersSemantic proximity Read ↗

Warburg Effect Reshapes Tumor Immunogenicity.Semantic proximity Read ↗

Genotype-specific precision tumor therapy using mitochondrial DNA mutation-induced drug release system.Semantic proximity Read ↗

Contact-based transfer of thymidylate promotes collective tumor growthSemantic proximity Read ↗

Fine-tuning chemical genetics to identify physiologic drug targets.Semantic proximity Read ↗

Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanomaSemantic proximity Read ↗

Supercharging T cell therapy with cancer mutations.Semantic proximity Read ↗

Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors.Semantic proximity Read ↗

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.